Hepatitis C News and Research

Latest Hepatitis C News and Research

Medivir initiates TMC649128 phase Ib trial in chronic hepatitis C

Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, today announces the start of a phase Ib clinical trial with TMC649128 intended for the treatment of chronic hepatitis C virus (HCV) infection.

22 Jun 2011

CDT biomarker poor, inaccurate method for detecting unhealthy drinking in HIV-infected adults

Researchers from Boston University School of Medicine (BUSM) have found that among HIV-infected adults with alcohol problems, measuring their carbohydrate-deficient transferrin (CDT) biomarker was a poor and inaccurate method for detecting unhealthy drinking.

21 Jun 2011

Study sheds new light on body's immune response to hepatitis A, C viruses

A surprising finding in a study comparing hepatitis C virus (HCV) with hepatitis A virus (HAV) infections in chimpanzees by a team that includes scientists from the Texas Biomedical Research Institute sheds new light on the nature of the body's immune response to these viruses.

21 Jun 2011

NanoViricides plans to lease new cGMP manufacturing and lab space

NanoViricides, Inc. announced today that it will be leasing new space for cGMP production of its nanoviricides drug candidates against various viral diseases.

20 Jun 2011

Australians getting fatter but living longer and smoking less: Health report card

Experts formulating a report on Australia’s health related figures say that Australian men and women are living longer than ever thanks to a drop in deaths from notorious diseases and cancer, but the rising weight has left the door open to a host of new health problems. The key finding of a major study released today was that excess weight carried by one in four children and more than 60 per cent of adults was contributing to an increase in chronic diseases across the country.

19 Jun 2011

FDA approves NULOJIX

Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration (FDA) approved NULOJIX, the first selective T-cell costimulation blocker indicated for the prophylaxis of organ rejection in adult patients receiving a kidney transplant, in combination with basiliximab induction, mycophenolate mofetil (MMF), and corticosteroids.

18 Jun 2011

Liver stiffness measurement could replace liver biopsy for evaluation of hepatitis C

Non-invasive tests for liver fibrosis, such as liver stiffness measurement or the FibroTest, can predict survival of patients with chronic hepatitis C, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute.

15 Jun 2011

Alios, Vertex sign worldwide license agreement to develop new hepatitis C combination medicines

Vertex Pharmaceuticals Incorporated and Alios BioPharma, Inc. today announced an exclusive worldwide licensing agreement that will add two distinct nucleotide analogues to Vertex's hepatitis C portfolio.

13 Jun 2011

MinuteClinic, OhioHealth enter affiliation to enhance high quality care services

MinuteClinic, the retail health care division of CVS Caremark, and OhioHealth, a nationally recognized not-for-profit, charitable health care organization based in Columbus, Ohio, have entered into a clinical affiliation that will enhance the high quality, affordable health care services they provide in central Ohio.

13 Jun 2011

Vertex VX-770 Phase 3 STRIVE study for cystic fibrosis demonstrates improvements in lung function

Vertex Pharmaceuticals Incorporated today announced the final results from its pivotal Phase 3 STRIVE study that evaluated VX-770, a medicine in development that targets the defective protein that causes cystic fibrosis (CF).

10 Jun 2011

Mortality from all causes higher among hepatitis C-infected patients, study finds

Although liver-related mortality among those infected with hepatitis C is well-documented, little is known about deaths in these patients that are not related to liver problems. A new study published in Clinical Infectious Diseases and now available online sought to determine mortality from all causes, including liver- and non-liver related deaths among hepatitis C patients in the general U.S. population. The analysis found mortality from all causes to be higher in these patients.

10 Jun 2011

NIAID awards Biota $2.9M grant for development of lead candidate for C. difficile

Biota Holdings Limited advises that its wholly owned subsidiary, Biota Scientific Management Pty Ltd, has been awarded a grant to fund the preclinical development of a lead candidate for the treatment of Clostridium difficile (C. difficile).

10 Jun 2011

Vertex announces interim results from VX-770 and VX-809 Phase 2 study on cystic fibrosis

Vertex Pharmaceuticals Incorporated today announced interim results from the first part of a Phase 2 study designed to evaluate multiple combination regimens of VX-770 and VX-809, Vertex's lead medicines in development that aim to treat the defective protein that causes cystic fibrosis.

9 Jun 2011

Cancer professionals urge world leaders to attend U.N. meeting on NCDs

The American Society of Clinical Oncology (ASCO) on Monday sent a letter signed by major U.S. medical societies representing about 300,000 health care professionals to the White House urging President Barack Obama to participate in the U.N. High Level Meeting on Noncommunicable Diseases that is scheduled for September, Agence France-Presse reports.

9 Jun 2011

Rockefeller, Scripps Research develop first genetically humanized mouse model for hepatitis C

Scientists at Rockefeller University and The Scripps Research Institute have developed the first genetically humanized mouse model for hepatitis C, an achievement that will enable researchers to test molecules that block entry of the hepatitis C virus into cells as well as potential vaccine candidates. The finding is reported in the June 9 issue of the journal Nature.

9 Jun 2011

Hepatitis C virus (HCV)-associated liver disease after liver transplantation

Hepatitis C virus (HCV)-associated liver disease continues to be the most common indication for liver transplantation (LT) in the United States accounting for nearly 50% of all liver transplants. Recurrence is universal in patients viremic at the time of transplantation with histological hepatitis developing in the majority of patients. Although the natural history of recurrent HCV is difficult to predict, it is widely accepted that cirrhosis from recurrent HCV occurs in up to 30% of patients within five years of transplantation.

8 Jun 2011

Intercell, Merck terminate V710 Phase II/III trial against S. aureus infection

Merck, known as MSD outside the United States and Canada, and Intercell AG (VSE: ICLL) today announced that following a detailed analysis of the data from the Phase II/III clinical trial evaluating V710, an investigational vaccine for the prevention of Staphylococcus aureus (S. aureus) infection, the independent Data Monitoring Committee (DMC) has unanimously recommended termination of the study.

8 Jun 2011

Hepatitis C News and Research

Latest Hepatitis C News and Research

Medivir initiates TMC649128 phase Ib trial in chronic hepatitis C

CDT biomarker poor, inaccurate method for detecting unhealthy drinking in HIV-infected adults

Study sheds new light on body's immune response to hepatitis A, C viruses

NanoViricides plans to lease new cGMP manufacturing and lab space

Australians getting fatter but living longer and smoking less: Health report card

FDA approves NULOJIX

Liver stiffness measurement could replace liver biopsy for evaluation of hepatitis C

Alios, Vertex sign worldwide license agreement to develop new hepatitis C combination medicines

MinuteClinic, OhioHealth enter affiliation to enhance high quality care services

Vertex VX-770 Phase 3 STRIVE study for cystic fibrosis demonstrates improvements in lung function

Mortality from all causes higher among hepatitis C-infected patients, study finds

NIAID awards Biota $2.9M grant for development of lead candidate for C. difficile

Vertex announces interim results from VX-770 and VX-809 Phase 2 study on cystic fibrosis

Cancer professionals urge world leaders to attend U.N. meeting on NCDs

Rockefeller, Scripps Research develop first genetically humanized mouse model for hepatitis C

Hepatitis C virus (HCV)-associated liver disease after liver transplantation

Intercell, Merck terminate V710 Phase II/III trial against S. aureus infection

Pharmasset expands PSI-7977 clinical trial for treatment of chronic hepatitis C

Hepatitis C patients with chronic liver disease may benefit from drinking coffee during treatment

NanoViricides' anti-influenza drug development studies to be presented at TechConnect World 2011

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Hepatitis C News and Research

Latest Hepatitis C News and Research

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Newsletters you may be interested in